Treatment-Resistant Depression -- Evaluation and Management
You have tried antidepressants. Maybe several. Maybe for years. And you are still depressed. Before concluding that your depression is untreatable, a thorough reassessment often reveals why previous treatments failed -- and what can actually work.
What Is Treatment-Resistant Depression?
Treatment-resistant depression (TRD) is conventionally defined as a major depressive episode that has not responded adequately to at least two antidepressant trials of adequate dose and duration -- typically at least 6 weeks at a therapeutic dose for each. It affects approximately 30% of people with major depressive disorder, representing millions of patients who have tried treatment and found it insufficient.
What I find most important to communicate to patients who arrive with this label is this: most "treatment-resistant" depression is not actually resistant to all treatment. What it is resistant to is inadequately dosed medication, treatment without addressing comorbidities, the wrong diagnosis entirely, or a narrow repertoire of options that excludes effective alternatives. A thorough reassessment changes the clinical picture in a significant proportion of cases.
In my cross-border practice, TRD patients from San Diego, Chula Vista, and Southern California arrive with extensive treatment histories that require careful review. Many have been on multiple SSRIs at subtherapeutic doses. Many have undiagnosed bipolar disorder that made antidepressant monotherapy not only ineffective but counterproductive. Many have untreated sleep disorders, hypothyroidism, or chronic pain that was perpetuating the depression regardless of what antidepressant was prescribed. The evaluation itself -- done properly -- is often the turning point.
The Most Common Reasons Depression Does Not Respond
Before concluding that a patient has true treatment-resistant depression, I systematically review the most common modifiable reasons prior treatments did not work.
Inadequate Dose or Duration
The most common reason antidepressants "fail" is that they were never given an adequate trial. Subtherapeutic doses, discontinuation before 6-8 weeks, or stopping at first side effects account for a large proportion of apparent non-response. Reviewing exactly what was taken, at what dose, for how long, and what happened is the starting point of every TRD evaluation.
Misdiagnosis -- Especially Bipolar
Bipolar depression is one of the most consequential misdiagnoses in psychiatry. It looks identical to unipolar depression -- but antidepressant monotherapy in bipolar disorder can trigger mixed states, rapid cycling, or mania. Many patients diagnosed with "treatment-resistant depression" actually have bipolar II disorder, where hypomanic episodes are mild enough to have been missed. A careful history resolves this -- and changes the entire treatment approach.
Untreated Comorbidities
Depression that co-occurs with untreated anxiety, ADHD, PTSD, substance use, chronic pain, or sleep disorders is highly unlikely to remit with antidepressants alone. Each comorbidity perpetuates the depressive state through different mechanisms. Identifying and treating all relevant comorbidities is not optional -- it is the difference between partial and full remission.
Medical Contributors
Hypothyroidism, anemia, vitamin D deficiency, sleep apnea, and chronic inflammatory conditions can all produce or perpetuate depression that does not respond to antidepressants because the biological driver is not being addressed. A complete medical review is part of every TRD evaluation in my practice.
Psychosocial Perpetuating Factors
Medication cannot resolve depression maintained by an abusive relationship, chronic workplace trauma, housing instability, or unprocessed grief. Identifying what in the patient's life is perpetuating the depression -- and whether it can be addressed -- determines whether pharmacological optimization alone is sufficient or whether psychosocial intervention is essential.
Pharmacogenomic Variability
Individual differences in drug metabolism affect both efficacy and tolerability of antidepressants. Patients who are poor metabolizers of certain SSRIs may experience toxicity at standard doses, while ultrarapid metabolizers may receive subtherapeutic levels. When the history suggests multiple failed trials with intolerable side effects, pharmacogenomic considerations inform medication selection.
The TRD Reassessment Process
A proper TRD evaluation is a systematic reconstruction of the patient's entire psychiatric and medical history. In my 60-minute initial consultation, I cover: a complete medication history (what was taken, dose, duration, response, reason for discontinuation), a thorough diagnostic review (including specific screening for bipolar disorder, PTSD, ADHD, anxiety disorders, and substance use), a medical review (thyroid, iron studies, B12, D3, sleep history), and a detailed assessment of current psychosocial stressors and life circumstances.
The goal is to answer one question before reaching for more aggressive treatment options: has this depression actually failed adequate treatment, or has it failed inadequate treatment? The answer to that question determines the entire subsequent approach.
What to bring to your first visit: A list of every psychiatric medication you have tried, including approximate doses and how long you took each one. Your most recent bloodwork if available (thyroid, CBC, B12, D3). Any prior psychiatric evaluations or therapy notes. This information dramatically accelerates the reassessment process.
Treatment Options for True TRD
When reassessment confirms that prior treatments were adequate and the depression has genuinely not responded, a range of evidence-based strategies are available. I discuss each option in detail, including what is accessible in our practice and what requires referral to specialized centers.
Augmentation Strategies
- Lithium augmentation -- among the most evidence-based strategies for TRD, often underused
- Atypical antipsychotic augmentation (aripiprazole, quetiapine, olanzapine) -- FDA-approved for MDD augmentation
- Thyroid hormone (T3) augmentation -- particularly effective when thyroid function is borderline
- Switching antidepressant class -- from SSRI to SNRI, TCA, or MAOI when appropriate
- Combination antidepressant therapy -- mirtazapine plus SSRI/SNRI (the "California rocket fuel" combination)
Newer Pharmacological Options
- Esketamine (Spravato) -- FDA-approved intranasal treatment for TRD, requires certified treatment centers
- Ketamine infusions -- rapid antidepressant effect within hours, available at specialized infusion centers
- Bupropion as augmentation or switch -- different mechanism from serotonergic agents
- Vortioxetine -- multimodal antidepressant with cognitive benefits relevant in TRD with cognitive symptoms
- MAOIs -- underused but highly effective, particularly for atypical TRD
Neuromodulation (Referral)
- Transcranial Magnetic Stimulation (TMS) -- non-invasive, FDA-approved, available in San Diego
- Electroconvulsive Therapy (ECT) -- most effective treatment for severe TRD, requiring hospitalization
- Vagus Nerve Stimulation (VNS) -- FDA-approved for chronic TRD
- Deep Brain Stimulation (DBS) -- investigational for severe refractory cases
- I coordinate referrals to appropriate centers in San Diego and Tijuana for these interventions
Psychotherapy Approaches
- Cognitive Behavioral Analysis System of Psychotherapy (CBASP) -- specifically developed for chronic depression
- Behavioral Activation -- particularly effective when motivation and anhedonia are primary
- EMDR -- when trauma history contributes to TRD
- Mindfulness-Based Cognitive Therapy (MBCT) -- evidence for preventing relapse in recurrent depression
- I coordinate referrals to bilingual therapists experienced with treatment-resistant presentations
Follow-up visits are $95 USD and can be conducted via telepsychiatry for established patients when clinically appropriate and where legally permitted.
Failed Treatment Is Not the Same as Untreatable
Most treatment-resistant depression has identifiable, addressable reasons for prior failure. A thorough reassessment is the first step toward a treatment that actually works. No referral needed.
TRD Reassessment for California Residents
Patients from San Diego, Chula Vista, National City, Oceanside, Los Angeles, and across Southern California with treatment-resistant depression frequently arrive having seen multiple providers without anyone conducting a comprehensive reassessment. They have been given a new antidepressant at each visit without a systematic review of why previous ones failed, without assessment for bipolar disorder, and without consideration of medical contributors.
A 60-minute reassessment at New City Medical Plaza, Paseo del Centenario 9580, Piso 25, Zona Urbana Rio Tijuana -- approximately 20 minutes from the San Ysidro border crossing -- provides exactly what most TRD patients have never received: a complete picture, a clear hypothesis about why treatment has not worked, and a structured plan addressing all contributing factors. We accept cash, credit cards, Zelle, and Venmo.
Frequently Asked Questions
I have tried five antidepressants. Does that mean nothing will ever work?
Could my depression actually be bipolar disorder that was missed?
Is ketamine or esketamine available at your practice?
What should I bring to a TRD reassessment to make it as useful as possible?
Psychiatrist trained at UNAM and Hospital Psiquiatrico Fray Bernardino Alvarez, Mexico's national reference center for psychiatric training. Certified by the Consejo Mexicano de Psiquiatria. Treatment-resistant depression -- particularly in patients who have lost hope after multiple failed trials -- is one of the most clinically demanding and most rewarding presentations to work with. The majority of cases I see labeled as TRD have identifiable, addressable reasons for prior failure. Getting to the root of those reasons is the work.
Scientific References
1. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). American Psychiatric Publishing.
2. Gaynes, B. N., et al. (2020). Defining treatment-resistant depression. Depression and Anxiety, 37(2), 134-145.
3. National Institute of Mental Health. (2023). Major Depression. Retrieved from https://www.nimh.nih.gov/health/statistics/major-depression
You Have Not Exhausted Your Options. You Have Exhausted the Wrong Ones.
A thorough reassessment changes the picture for most patients labeled as treatment-resistant. The next step is clarity, not another trial in the dark.